

CO2-L

Bicarbonate liquid

Order information

REF	CONTENT	Analyzer(s) on which cobas c pack(s) can be used
03289923 190	Bicarbonate liquid (250 tests)	System-ID 07 6725 5 COBAS INTEGRA 400 plus COBAS INTEGRA 800
20751995 190	Ammonia/Ethanol/CO ₂ Calibrator (2 × 4 mL)	System-ID 07 5199 5
20752401 190	Ammonia/Ethanol/CO ₂ Control Normal (5 × 4 mL)	System-ID 07 5240 1
20753009 190	Ammonia/Ethanol/CO ₂ Control Abnormal (5 × 4 mL)	System-ID 07 5300 9
12149435 122	Precinorm U plus (10 × 3 mL)	System-ID 07 7999 7
12149435 160	Precinorm U plus (10 × 3 mL, for USA)	System-ID 07 7999 7
12149443 122	Precipath U plus (10 × 3 mL)	System-ID 07 8000 6
12149443 160	Precipath U plus (10 × 3 mL, for USA)	System-ID 07 8000 6

English

System information

Test CO2-L, test ID 0-625

Intended use

In vitro test for the quantitative determination of the bicarbonate (HCO₃⁻) concentration in human serum and plasma on COBAS INTEGRA systems.

Summary

Bicarbonate is the second largest fraction of the anions in plasma. Included in this fraction are the bicarbonate (HCO₃⁻) and carbonate (CO₃²⁻) ions, as well as the carbamino compounds. At the physiological pH of blood, the concentration of carbonate is 1/1000 that of bicarbonate. The carbamino compounds are also present in such low quantities that they are generally not mentioned specifically.

Several different methods for the determination of bicarbonate in serum and plasma have been reported. Most of these procedures utilize acidification of the sample and conversion of all carbon dioxide forms to CO₂ gas.¹ The amount of gas formed is measured by manometric or volumetric devices, ion selective electrodes, or spectrophotometric techniques.^{2,3} These methods are either cumbersome, time-consuming, technique-oriented, and/or require special equipment.

Enzymatic procedures using phosphoenolpyruvate carboxylase (PEPC) have been described.^{4,5}


The bicarbonate content of serum or plasma is a significant indicator of electrolyte dispersion and anion deficit. Together with pH determination, bicarbonate measurements are used in the diagnosis and treatment of numerous potentially serious disorders associated with acid-base imbalance in the respiratory and metabolic systems.

Test principle

Bicarbonate reacts with phosphoenolpyruvate (PEP) in the presence of PEPC to produce oxaloacetate and phosphate:



The above reaction is coupled with one involving the transfer of a hydrogen ion from NADH analog to oxaloacetate using MDH.



The resultant consumption of NADH analog causes a decrease in absorbance at 409 nm, which is proportional to the concentration of bicarbonate in the sample being assayed.

Reagents - working solutions

R Phosphoenolpyruvate: ≥ 40 mmol/L; NADH analog: ≥ 2 mmol/L; MDH (porcine): ≥ 314.3 µkat/L; PEPC (microbial): ≥ 30.8 µkat/L

R is in position B.

Precautions and warnings

Pay attention to all precautions and warnings listed in Section 1 / Introduction of this Method Manual.

Reagent handling

Ready for use

Storage and stability

Shelf life at 2-8 °C

See expiration date on **cobas c** pack label

COBAS INTEGRA 400 plus system

On-board in use at 10-15 °C

6 weeks

COBAS INTEGRA 800 system

On-board in use at 8 °C

6 weeks

Specimen collection and preparation

For specimen collection and preparation only use suitable tubes or collection containers.

Only the specimens listed below were tested and found acceptable.

Serum

Plasma: Heparin (Li-, Na-, NH₄⁺) plasma

The preferred specimen is from venous blood collected anaerobically in the usual manner for bicarbonate analysis. Bicarbonate content in uncapped tubes decreases approximately 4 mmol/L after one hour.⁶ It has been reported that alkalinized serum stored in open cups is stable for up to 4 hours.⁶

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

Separate from erythrocytes and store tightly stoppered.

Stability:

7 days at 4 °C⁷

40 hours at 15-25 °C^{8,9}

Storage of serum at -20 °C or -80 °C for up to 6 months had no significant effect.¹⁰

Materials provided

See "Reagents – working solutions" section for reagents.

Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

Application for serum and plasma

COBAS INTEGRA 400 plus test definition

Measuring mode	Absorbance
Abs. calculation mode	Endpoint
Reaction mode	R-S
Reaction direction	Decrease
Wavelength A/B	409/512 nm
Calc. first/last	21/45

CO₂-L

Bicarbonate liquid

cobas[®]

Substrates

Unit mmol/L

Pipetting parameters

		Diluent (H ₂ O)
R	50 µL	120 µL
Sample	2 µL	10 µL
Total volume	182 µL	

COBAS INTEGRA 800 test definition

Measuring mode	Absorbance
Abs. calculation mode	Endpoint
Reaction mode	R-S
Reaction direction	Decrease
Wavelength A/B	409/512 nm
Calc. first/last	24/67
Postdilution factor	No
Unit	mmol/L

Pipetting parameters

		Diluent (H ₂ O)
R	50 µL	120 µL
Sample	2 µL	10 µL
Total volume	182 µL	

Calibration

Calibrator	Roche Ammonia/Ethanol/CO ₂ Calibrator Use deionized water as zero calibrator.
Calibration mode	Linear regression
Calibration replicate	Duplicate recommended
Calibration interval	Each lot and as required following quality control procedures

Traceability: This method has been standardized against a primary standard.

Quality control

Reference range	Roche Ammonia/Ethanol/CO ₂ Control Normal or Precinorm U plus
Pathological range	Roche Ammonia/Ethanol/CO ₂ Control Abnormal or Precipath U plus
Control interval	24 hours recommended
Control sequence	User defined
Control after calibration	Recommended

For quality control, use control materials as listed in the "Order information" section. In addition, other suitable control material can be used.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

Calculation

COBAS INTEGRA analyzers automatically calculate the analyte concentration of each sample. For more details, please refer to Data Analysis in the Online Help (COBAS INTEGRA 400 plus/800 analyzers).

Conversion factor: mmol/L × 1 = mEq/L¹¹

Limitations - interference

Criterion: Recovery within ± 10 % of initial value.

Icterus:¹² No significant interference up to an I index of 60 for conjugated and unconjugated bilirubin (approximate conjugated and unconjugated bilirubin concentration: 1026 µmol/L or 60 mg/dL).

Hemolysis:¹² No significant interference up to an H index of 1000 (approximate hemoglobin concentration: 621 µmol/L or 1000 mg/dL).

Lipemia (Intralipid):¹² No significant interference up to an L index of 2000. There is poor correlation between the L index (corresponds to turbidity) and triglycerides concentration.

Drugs: No interference was found at therapeutic concentrations using common drug panels.^{13,14}

In very rare cases, gammopathy, in particular type IgM (Waldenström's macroglobulinemia), may cause unreliable results.¹⁵

An abnormally elevated concentration of ambient carbon dioxide (CO₂) may occur under certain environmental conditions in the laboratory. The fluctuating ambient CO₂ concentration may interfere with the CO₂-L assay leading to higher CO₂ results. Under these circumstances, the reduction of the re-calibration interval may become necessary if the laboratory is unable to keep the ambient CO₂ concentration at a normal level by appropriate countermeasures.

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

ACTION REQUIRED

Special wash programming: The use of special wash steps is mandatory when certain test combinations are run together on COBAS INTEGRA analyzers. Refer to the Method Manual, Introduction, Extra Wash Cycles for further instructions.

Where required, special wash/carry-over evasion programming must be implemented prior to reporting results with this test.

Limits and ranges**Measuring range**

2.0-50 mmol/L (2.0-50 mEq/L)

Lower limits of measurement

Lower detection limit of the test:

2.0 mmol/L (2.0 mEq/L)

The lower detection limit represents the lowest measurable analyte level that can be distinguished from zero. It is calculated as the value lying 3 standard deviations above that of the lowest standard (lowest standard + 3 SD, repeatability, n = 21).

Expected values

22-29 mmol/L (22-29 mEq/L)¹

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

Specific performance data

Representative performance data on the COBAS INTEGRA analyzers are given below. Results obtained in individual laboratories may differ.

Precision

Precision was determined using human samples and controls in an internal protocol with repeatability (n = 21) and intermediate precision (3 aliquots per run, 1 run per day, 21 days). The following results were obtained:

	Level 1	Level 2
Mean	19.7 mmol/L (19.7 mEq/L)	35.4 mmol/L (35.4 mEq/L)
CV repeatability	0.6 %	0.5 %
	Level 1	Level 2
Mean	16.8 mmol/L (16.8 mEq/L)	28.8 mmol/L (28.8 mEq/L)
CV intermediate precision	3.5 %	3.8 %

CO₂-L

Bicarbonate liquid**cobas®****Substrates****Method comparison**

Bicarbonate values for human serum and plasma samples obtained on a COBAS INTEGRA 800 analyzer using the COBAS INTEGRA Bicarbonate liquid reagent (y) were compared to those determined using the COBAS INTEGRA Carbon Dioxide reagent (CO₂-S) on a COBAS INTEGRA 800 analyzer (x) and using the Bicarbonate liquid assay on a Roche/Hitachi 917 analyzer (x).

COBAS INTEGRA 800 analyzer	Sample size (n) = 57
Passing/Bablok ¹⁶	Linear regression
$y = 0.981x + 0.176 \text{ mmol/L}$	$y = 0.974x + 0.348 \text{ mmol/L}$
$r = 0.984$	$r = 0.999$
SD (md 95) = 0.400	Sy.x = 0.195
The sample concentrations were between 1.13 and 46.2 mmol/L (1.13 and 46.2 mEq/L)	

Roche/Hitachi 917 analyzer	Sample size (n) = 57
Passing/Bablok ¹⁶	Linear regression
$y = 1.010x + 0.128 \text{ mmol/L}$	$y = 1.006x + 0.427 \text{ mmol/L}$
$r = 0.969$	$r = 0.998$
SD (md 95) = 1.06	Sy.x = 0.434
The sample concentrations were between 1.1 and 44.3 mmol/L (1.1 and 44.3 mEq/L).	

References

- Scott MG, Heusel JW, LeGrys VA, et al. Electrolytes and blood gases, in Tietz NW. Textbook of Clinical Chemistry. 3rd ed. Philadelphia, PA: WB Saunders Co 1999;1065-1066.
- Natelson S. Microtechniques of Clinical Chemistry. Springfield, IL: Charles C Thomas 1975;147.
- Segal MA. A rapid electrotitrimetric method for determining CO₂ combining power in plasma or serum. Am J Clin Pathol 1955;25:1212-1216.
- Wilson W, Jesyk P, Rand R, et al. Use of Vickers discrete analyzer for enzymatic determination of the bicarbonate content of serum. Clin Chem 1973;19(6):640.
- Norris KA, Atkinson AR, Smith WG, et al. Colorimetric enzymatic determination of serum total carbon dioxide, as applied to the Vickers Multichannel 300 discrete analyzer. Clin Chem 1975;21:1093-1101.
- Gambino SR, Schreiber H. The measurement of CO₂ content with the autoanalyzer. A comparison with 3 standard methods and a description of a new method (alkalinization) for preventing loss of CO₂ from open cups. Am J Clin Path 1966;45:406.
- Guder WG, da Fonseca-Wollheim F, Heil W, et al. Quality of Diagnostic Samples, in brochure: Recommendations of the Working Group on Preanalytical Quality of the German Society for Clinical Chemistry and Laboratory Medicine, 3rd Ed. 2010.
- Boyanton BL, Blick KE. Stability studies of Twenty-Four Analytes in Human Plasma and Serum. Clin Chem 2002;48/12:2242-2247.
- O'Keane MP, Cunningham SK. Evaluation of three different specimen types (serum, plasma lithium heparin and serum gel separator) for analysis of certain analytes: clinical significance of differences in results and efficiency in use. Clin Chem Lab Med 2006;44(5):662-668.
- Elfath D, Cooney J, McDaniel R, et al. Effect of frozen storage of serum on the level of 22 chemistry analytes. Clin Chem 1991;37:931.
- Tietz NW, ed. Clinical Guide to Laboratory Tests, 3rd ed. Philadelphia PA: WB Saunders Company 1995;84.
- Glick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. Clin Chem 1986;32:470-475.
- Breuer J. Report on the Symposium "Drug effects in Clinical Chemistry Methods". Eur J Clin Chem Clin Biochem 1996;34:385-386.
- Sonntag O, Scholer A. Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies. Ann Clin Biochem 2001;38:376-385.

- Bakker AJ, Mücke M. Gammopathy interference in clinical chemistry assays: mechanisms, detection and prevention. Clin Chem Lab Med 2007;45(9):1240-1243.
- Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem 1988 Nov;26(11):783-790.

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard.

CONTENT

Contents of kit

Volume after reconstitution or mixing

FOR US CUSTOMERS ONLY: LIMITED WARRANTY

Roche Diagnostics warrants that this product will meet the specifications stated in the labeling when used in accordance with such labeling and will be free from defects in material and workmanship until the expiration date printed on the label. THIS LIMITED WARRANTY IS IN LIEU OF ANY OTHER WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE. IN NO EVENT SHALL ROCHE DIAGNOSTICS BE LIABLE FOR INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES.

COBAS, COBAS C, COBAS INTEGRA, PRECINORM and PRECIPATH are trademarks of Roche.

All other product names and trademarks are the property of their respective owners.

Significant additions or changes are indicated by a change bar in the margin.

© 2013, Roche Diagnostics



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim
www.roche.com

Distribution in USA by:
Roche Diagnostics, Indianapolis, IN
US Customer Technical Support 1-800-428-2336

